The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis
暂无分享,去创建一个
[1] S. Imafuku,et al. Clinical characteristics of Japanese pustular psoriasis: A multicenter observational study , 2021, The Journal of dermatology.
[2] A. Morita,et al. Clinical characteristics and health‐care resource utilization in patients with generalized pustular psoriasis using real‐world evidence from the Japanese Medical Data Center database , 2021, The Journal of dermatology.
[3] A. Morita,et al. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database , 2021, The Journal of dermatology.
[4] H. Yasunaga,et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. , 2021, Journal of the American Academy of Dermatology.
[5] Qing Luo,et al. An update on genetic basis of generalized pustular psoriasis (Review) , 2021, International journal of molecular medicine.
[6] W. Valdecantos,et al. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States , 2021, Current medical research and opinion.
[7] J. Crowley,et al. A brief guide to pustular psoriasis for primary care providers , 2020, Postgraduate medicine.
[8] M. Mockenhaupt,et al. Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease , 2020, American journal of human genetics.
[9] D. Esser,et al. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review , 2020, Expert review of clinical immunology.
[10] A. Ekici,et al. Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis. , 2020, The Journal of investigative dermatology.
[11] M. Akiyama,et al. Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects , 2019, American Journal of Clinical Dermatology.
[12] Masaru Tanaka,et al. Case of generalized pustular psoriasis with coexisting mutations in IL36RN and CARD14 , 2019, The Journal of dermatology.
[13] A. Olry,et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database , 2019, European Journal of Human Genetics.
[14] M. Lebwohl,et al. An update on generalized pustular psoriasis , 2019, Expert review of clinical immunology.
[15] Kristen M Beck,et al. Diagnosis and screening of patients with generalized pustular psoriasis , 2019, Psoriasis.
[16] Adriana Rendon,et al. Psoriasis Pathogenesis and Treatment , 2019, International journal of molecular sciences.
[17] Kaspar Torz,et al. Clinical and genetic differences between pustular psoriasis subtypes , 2018, The Journal of allergy and clinical immunology.
[18] M. Akiyama,et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP , 2018, The Journal of dermatology.
[19] Qianyi Yang,et al. Genetic polymorphism of IL36RN in Han patients with generalized pustular psoriasis in Sichuan region of China , 2018, Medicine.
[20] A. Navarini,et al. Generalized pustular psoriasis – a model disease for specific targeted immunotherapy, systematic review , 2018, Experimental dermatology.
[21] S. Jo,et al. Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database , 2017, Annals of dermatology.
[22] L. Naldi,et al. European consensus statement on phenotypes of pustular psoriasis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[23] D. Kivelevitch,et al. Pustular psoriasis: pathophysiology and current treatment perspectives , 2016, Psoriasis.
[24] Daisuke Koide,et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database , 2015, BMJ Open.
[25] Hong Liu,et al. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris. , 2014, Journal of dermatological science.
[26] N. Lai,et al. Clinical profile, morbidity, and outcome of adult‐onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia , 2014, International journal of dermatology.
[27] M. Akiyama,et al. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. , 2014, The Journal of investigative dermatology.
[28] Fernanda Mendes Araújo,et al. Pustular psoriasis of pregnancy (Impetigo herpetiformis) - Case report* , 2013, Anais brasileiros de dermatologia.
[29] E. Cowen,et al. Autoinflammatory pustular neutrophilic diseases. , 2013, Dermatologic clinics.
[30] M. Simpson,et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. , 2011, American journal of human genetics.
[31] A. Smahi,et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.
[32] M. Black,et al. Effect of Pregnancy on Other Skin Disorders , 2008 .
[33] J. Nicolas,et al. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. , 2006, European journal of dermatology : EJD.
[34] M. Rybojad,et al. High frequency of cholestasis in generalized pustular psoriasis: Evidence for neutrophilic involvement of the biliary tract , 2004, Hepatology.
[35] T. Tezuka,et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity , 2003, Archives of Dermatological Research.
[36] S. Imamura,et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. , 1996, Acta dermato-venereologica.
[37] S. Muller,et al. Generalized pustular psoriasis. A review of 63 cases. , 1991, Archives of dermatology.